CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway
Open Access
- 19 October 2023
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 43 (11) , 1244-1266
Abstract
Background: As a rapid‐progressing tumor, breast malignant phyllodes tumors (PTs) are challenged by the lack of effective therapeutic strategies and suitable prognostic markers. This study aimed to clarify the role and mechanism of CD146 on promoting PTs malignant progression, and to identify a novel prognosis marker and treatment target of breast malignant PTs. Methods: The expression and prognostic significance of CD146 in PTs was detected through single‐cell RNA‐sequencing (scRNA‐seq), immunostaining, real‐time PCR and other methodologies. Functional experiments including proliferation assay, colony formation assay, transwell assay, and collagen contraction assay were conducted to validate the role of CD146 in malignant progression of PTs. The efficacy of anti‐CD146 monoclonal antibody AA98 against malignant PTs was corroborated by a malignant PT organoid model and a PT patient‐derived xenograft (PDX) model. Transcriptome sequencing, proteomic analysis, co‐immunoprecipitation, and pull‐down assay was employed to identify the modulating pathway and additional molecular mechanism. Results: In this study, the scRNA‐seq analysis of PTs disclosed a CD146‐positive characteristic in the α‐SMA + fibroblast subset. Furthermore, a progressive elevation in the level of CD146 was observed with the malignant progression of PTs. More importantly, CD146 was found to serve as an independent predictor for recurrence in PT patients. Furthermore, CD146 was found to augment the viability and invasion of PTs. Mechanistically, CD146 acted as a protective “shield” to prevent the degradation of Discoidin, CUB, and LCCL domain‐containing protein 2 (DCBLD2), thereby activating the phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) signaling pathway and enhancing malignant behaviors of PT cells. In the malignant PT organoid and PDX model, a significant suppression of malignant PT growth was observed after the application of AA98. Conclusions: These findings suggested that CD146 served as an efficacious marker for predicting PT malignant progression and showed promise as a prognosis marker and treatment target of breast malignant PTs. The study further unveiled the essential role of the CD146‐DCBLD2/PI3K/AKT axis in the malignant progression of PTs.Keywords
Funding Information
- Natural Science Foundation of China (82173054)
- Natural Science Foundation of China (81621004)
- Natural Science Foundation of China (81720108029)
- Natural Science Foundation of China (82002782)
- National Natural Science Foundation of China (82173054)
- National Natural Science Foundation of China (81621004)
- National Natural Science Foundation of China (81720108029)
- National Natural Science Foundation of China (82002782)
- Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515110069)
- Guangdong Provincial Department of Science and Technology (2022B1515020048)
This publication has 67 references indexed in Scilit:
- Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunitiesOrphanet Journal of Rare Diseases, 2013
- CD146 and insulin-like growth factor 2 mRNA-binding protein 3 predict prognosis of asbestos-induced rat mesotheliomaCancer Science, 2013
- Tumor suppressor Hippo/MST1 kinase mediates chemotaxis by regulating spreading and adhesionProceedings of the National Academy of Sciences, 2012
- CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancerProceedings of the National Academy of Sciences, 2011
- Endothelial and Smooth Muscle-derived Neuropilin-like Protein Regulates Platelet-derived Growth Factor Signaling in Human Vascular Smooth Muscle Cells by Modulating Receptor UbiquitinationJournal of Biological Chemistry, 2009
- CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cellsOncogene, 2007
- In-gel digestion for mass spectrometric characterization of proteins and proteomesNature Protocols, 2006
- A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growthBlood, 2003
- Phyllodes tumoursPostgraduate Medical Journal, 2001
- Phyllodes Tumor of the BreastPathology - Research and Practice, 1994